---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-249487"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:32:30.005086+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regeneron and Intellia expand CRISPR collaboration to neurological and muscular diseases

## Summary
- Uses Regeneron's antibody-targeted AAV vectors and Intellia's Nme2CRISPR/Cas9 for in vivo delivery.
- Initial research on two non-liver targets for neurological and muscular diseases.
- Each company may lead development/commercialization for one target; co-development option available.
- Builds on existing successful collaboration between the two firms.

## SEC filing metadata
- accession: 0001193125-23-249487
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312523249487/0001193125-23-249487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312523249487/d556975d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-249487
- JSON: https://secwatch.observer/filing/0001193125-23-249487.json
- Plain text: https://secwatch.observer/filing/0001193125-23-249487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.